ACELYRIN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.73 USD | +0.85% |
|
+2.38% | -36.60% |
| 09/05 | Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024 | CI |
| 09/05 | Acelyrin, Inc. Announces CEO Changes | CI |
Chart calendar Acelyrin, Inc.
bc1.wi3dV6F2-8yb0v0Wm7nTFB24Z1CuhCEakmM-k87BKo4.jnuRJ_I7z-G2o8xwotiUVy__PR_Ex3dX8ypX4JajEtiIVKcT8TCWu8-8pA~149ebad189e575212898507877414b65
Upcoming events on Acelyrin, Inc.
Past events on Acelyrin, Inc.
| 14/05/2024 02:00 am | Q1 2024 Earnings Call |
| 13/05/2024 | Q1 2024 Earnings Release |
| 29/03/2024 01:35 am | Q4 2023 Earnings Release |
| 20/03/2024 06:00 pm | Lonigutamab Phase 1/2 Proof of concept Data in Thyroid Eye Disease Call |
| 11/03/2024 | Investor Meeting |
| 15/02/2024 | Investor Meeting |
| 16/11/2023 02:30 pm | Jefferies London Healthcare Conference |
| 08/11/2023 03:00 am | Q3 2023 Earnings Call |
| 08/11/2023 02:35 am | Q3 2023 Earnings Release |
| 13/09/2023 09:00 pm | Morgan Stanley Global Healthcare Conference |
| 12/09/2023 03:00 am | Izokibep Phase 2b/3 Trial Results Call |
| 15/08/2023 02:00 am | Q2 2023 Earnings Call |
| 15/08/2023 01:35 am | Q2 2023 Earnings Release |
| 16/06/2023 01:35 am | Q1 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2022 | 2023 | 2024 |
|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | 0,00 -416 - | -416 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -422 -418 -0.93% | -367 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -382 -386 1.23% | -360 |
|
Net income Million USD | Released Forecast Spread | -64,8 | -382 -386 1.23% | -360 |
|
EPS USD | Released Forecast Spread | -21,1 | -5,43 -7,14 23.92% | -3,84 |
| Announcement Date | 13/04/23 | 28/03/24 | - |
Quarterly results
| Fiscal Period | December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | |
|
EBITDA Million USD | Released Forecast Spread | -99,1 | -101 | -103 | -105 | ||||
|
EBIT Million USD | Released Forecast Spread | -42,7 -59,8 28.64% | -94,4 -46,1 -104.82% | -105 -99,3 -5.9% | -87,7 | -89,7 | -90,8 | -94,6 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -26,0 -60,7 57.13% | -83,9 -41,7 -101.42% | -95,2 -95,0 -0.2% | -88,7 | -91,1 | -93,2 | -95,3 | |
|
Net income Million USD | Released Forecast Spread | -176 | -26,0 -60,7 57.13% | -83,9 -41,7 -101.42% | -95,2 -95,0 -0.2% | -88,7 | -91,1 | -93,2 | -95,3 |
|
EPS USD | Released Forecast Spread | -8,61 | -0,40 -0,85 52.66% | -0,87 -0,47 -86.7% | -0,75 -0,99 23.93% | -0,92 | -0,95 | -0,97 | -1,02 |
| Announcement Date | 15/06/23 | 14/08/23 | 07/11/23 | 28/03/24 | - | - | - | - |
| 16/05/2024 | BIOCON LIMITED: Q4 2024 Earnings Release |
| 16/05/2024 06:30 pm | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 17/05/2024 04:30 pm | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 24/07/2024 | VIKING THERAPEUTICS, INC.: Q2 2024 Earnings Release (Projected) |
| 25/07/2024 | BIOCON LIMITED: Q1 2025 Earnings Release (Projected) |
| 25/07/2024 10:30 am | ARGENX SE: Q2 2024 Earnings Release |
| 30/07/2024 | RHYTHM PHARMACEUTICALS, INC.: Q2 2024 Earnings Release (Projected) |
| 30/07/2024 | NEUROCRINE BIOSCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
| 30/07/2024 | CEREVEL THERAPEUTICS HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
| 31/07/2024 | CASSAVA SCIENCES, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Acelyrin, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- SLRN Stock
- Calendar Acelyrin, Inc.